GleamWall
中文EN

QNRX Quoin Pharmaceuticals Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1671502

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-142.5%
ROA-95.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.4%
Debt / equity0.00x
Current ratio7.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$9.80M$3.60M
SG&A expense$6.49M$5.93M
Pretax income-$15.80M-$8.96M
Net income-$15.80M-$8.96M
EPS (diluted)——
Balance sheet
Cash & equivalents$3.82M$3.62M
Short-term investments$14.93M$10.43M
Current assets$20.01M$14.93M
Intangibles$383,334$483,334
Total assets$20.39M$15.71M
Current liabilities$5.55M$4.18M
Total liabilities$7.27M$6.50M
Shareholders' equity$13.12M$9.20M
Shares outstanding52.44M8.95M
Cash flow statement
Operating cash flow-$13.54M-$7.86M
Investing cash flow-$4.28M-$1.89M
Financing cash flow$18.01M$10.97M
Stock-based compensation$1.15M$1.26M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.